QGEN vs. RGEN: Qiagen vs. Repligen Stock Comparison
How do Qiagen (QGEN) and Repligen (RGEN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Qiagen (QGEN) and Repligen (RGEN) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.
| Profile Item | QGEN | RGEN |
|---|---|---|
| Name | Qiagen N.V. | Repligen Corporation |
| Country/Region | Netherlands | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| GICS Sub-Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| Market Capitalization | 10.39 billion USD | 11.09 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | June 28, 1996 | April 29, 1986 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | QGEN | RGEN |
|---|---|---|
| Total Return (1Y) | 17.09% | 23.28% |
| Total Return (3Y, Annualized) | 10.44% | 6.20% |
| Total Return (5Y, Annualized) | -0.72% | -8.41% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | QGEN | RGEN |
|---|---|---|
| Volatility (1Y, Annualized) | 35.52% | 46.73% |
| Beta (5Y) | 0.56 | 1.11 |
| Max Drawdown (5Y) | -41.97% | -64.67% |
| Avg. Volume (3M) | 3.68M | 1.18M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | QGEN | RGEN |
|---|---|---|
| Sharpe Ratio (1Y) | 0.36 | 0.41 |
| Sortino Ratio (1Y) | 0.60 | 0.60 |
Profitability
ROE (TTM)
Repligen (RGEN) reports a negative ROE of -0.57%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Qiagen (QGEN) reports 10.81%, ranking against industry peers normally.
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.81%
- Max
- 109.18%
- QGEN
- 10.81%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.57%
- Max
- 109.18%
- Q3
- 6.23%
- RGEN
- -0.57%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Repligen (RGEN) reports a negative net margin of -1.47%, usually indicating a net loss over the period. Meanwhile Qiagen (QGEN) reports 18.20%, ranking against industry peers normally.
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.20%
- QGEN
- 18.20%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-1.47%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- RGEN
- -1.47%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Qiagen (QGEN) at 27.75% operates in the top operating margin quartile, ahead of Repligen (RGEN) at 6.19%, which runs around its industry’s norm.
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
27.75%
- Max
- 83.12%
- QGEN
- 27.75%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.19%
- Max
- 83.12%
- Q3
- 14.77%
- RGEN
- 6.19%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | QGEN | RGEN |
|---|---|---|
| ROE (TTM) | 10.81% | -0.57% |
| ROA (TTM) | 5.68% | 1.40% |
| Net Margin (TTM) | 18.20% | -1.47% |
| Operating Margin (TTM) | 27.75% | 6.19% |
| Gross Margin (TTM) | 67.06% | 53.77% |
Growth
Revenue Growth
Both Qiagen (QGEN) at 5.65% and Repligen (RGEN) at 16.36% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: Qiagen (QGEN) reports EPS growth of 409.76%, ranked against its industry; Repligen (RGEN) has no EPS growth figure this period.
Growth Metrics
| Metric | QGEN | RGEN |
|---|---|---|
| Revenue Growth (YoY) | 5.65% | 16.36% |
| Revenue Growth (3Y CAGR) | -0.81% | -2.70% |
| EPS Growth (YoY) | 409.76% | -- |
| EPS Growth (3Y CAGR) | -0.19% | -35.73% |
Financial Strength
Current Ratio (MRQ)
Both Qiagen (QGEN) at 2.63 and Repligen (RGEN) at 9.88 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.63
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- QGEN
- 2.63
- Q1
- 2.47
- Min
- 0.10
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.88
- Max
- 25.13
- Q3
- 12.13
- RGEN
- 9.88
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both Qiagen (QGEN) at 0.47 and Repligen (RGEN) at 0.33 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.47
- Max
- 1.42
- Q3
- 0.65
- QGEN
- 0.47
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.33
- Max
- 1.42
- Q3
- 0.65
- RGEN
- 0.33
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | QGEN | RGEN |
|---|---|---|
| Current Ratio (MRQ) | 2.63 | 9.88 |
| Debt / Equity (MRQ) | 0.47 | 0.33 |
| Net Debt / EBITDA | 1.08 | -1.19 |
Dividends
Dividend Yield (TTM)
Repligen (RGEN) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Qiagen (QGEN) reports a yield of 0.71%, ranking against industry peers normally.
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.71%
- QGEN
- 0.71%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- RGEN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Repligen (RGEN) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Qiagen (QGEN) reports a payout of 18.21%, ranking against industry peers normally.
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.21%
- QGEN
- 18.21%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- RGEN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | QGEN | RGEN |
|---|---|---|
| Dividend Yield (TTM) | 0.71% | 0.00% |
| Dividend Payout Ratio (TTM) | 18.21% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Qiagen (QGEN) trades at 27.21 times trailing earnings, ranked against its peers, while Repligen (RGEN) has no P/E ratio this period.
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
27.21
- Max
- 85.34
- Q3
- 43.46
- QGEN
- 27.21
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- RGEN
- --
P/S Ratio (TTM)
On P/S ratio, both Qiagen (QGEN) at 4.91 and Repligen (RGEN) at 13.77 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.91
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- QGEN
- 4.91
- Q1
- 3.01
- Min
- 0.01
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.77
- Max
- 58.18
- Q3
- 25.77
- RGEN
- 13.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Qiagen (QGEN) at 2.99 and Repligen (RGEN) at 4.70 are valued close to their industries’ norm against book — neither stands out from peers.
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.99
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- QGEN
- 2.99
- Q1
- 1.69
- Min
- -5.59
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.70
- Max
- 13.53
- Q3
- 6.54
- RGEN
- 4.70
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | QGEN | RGEN |
|---|---|---|
| P/E Ratio (TTM) | 27.21 | -- |
| P/S Ratio (TTM) | 4.91 | 13.77 |
| P/B Ratio (MRQ) | 2.99 | 4.70 |
| Free Cash Flow Yield (TTM) | 3.62% | 1.01% |